17,261 trials
Parkinson · Tremor
Primary: Unified Parkinsons Disease Rating Scale (UPDRS) Tremor Scale — 0; 8 participants — p=0.0007
Multiple Sclerosis
Primary: Measure: Number of Subjects With Adverse Events, Number of Abnormalities in Safety Assessments — 12; 8 participants
Oral Herpes Simplex
Primary: Number of Participants for Whom a Recurrent Oral Herpes Episode Initiated With Prodromal Symptoms Were Aborted Before Progressing to a Lesion as Assessed by a Trained…
ER Positive, Her2 Negative Breast Cancer Patients · Triple Negative Breast Cancer Patients
Primary: Number of Participants With Pathologic Complete Response (pCR) (Rate of pCR) — 59; 29; 32; 14 participants
Benign Paroxysmal Positional Vertigo
Primary: Conversion in Direction of Nystagmus From Apogeotropic to Geotropic or Disappearance of Nystagmus — 51; 46; 38 participants — p=0.02839
Obesity
Primary: Assessment of the % Excess Weight Loss at Week 52 or Last Assessment — 26.9 %EWL
Traumatic Brain Injury · Subarachnoid Hemorrhage · Intracerebral Hemorrhage
Primary: Number of Units of Packed Red Blood Cell Transfused — 0.9; 1.5 units — p=0.03
Pneumonia, Bacterial
Primary: Percentage of Participants With Clinical Response at Test of Cure (TOC) Visit — 90.0; 87.5; 62.5; 10.0 percentage of participants
Breast Cancer
Primary: Maximum Tolerated Dose (MTD) — 0; 0 participants with DLT
Adult Nasal Type Extranodal NK/T-Cell Lymphoma · Anaplastic Large Cell Lymphoma · Angioimmunoblastic T-Cell Lymphoma
Primary: Objective Response Rate (Complete Responses (CR) + Partial Responses (PR)) — 2; 7; 28 participants
Stroke
Primary: Upper Extremity Component of Fugl-Meyer Assessment — 35.3; 32.6; 0.9; 0.8 units on a scale
Oesophagitis, Eosinophilic
Primary: Number of Participants With Any Adverse Events (AE), Any Serious Adverse Event (SAE) and Drug-related AE During Treatment Phase (TP) and Follow-up Phase (FP) — 18; 15…
Gastrointestinal Stromal Tumor
Primary: Percentage of Participants Showing Clinical Benefit Based on Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.0 — 18.5 percentage of participants
Fallopian Tube Cancer · Female Reproductive Cancer · Recurrent Breast Cancer
Primary: Incidence of Dose-limiting Toxicity (DLT), Graded Using the National Cancer Institute (NCI) Common Toxicity Criteria (CTC) Version 4.0 (Phase I) — 1; 1; 2; 0 participants
Head and Neck Cancer
Primary: Overall Response Rate — 0 patients